Evaluation of Cardiac Burden in Patients With Sever Bronchial AsthmaNCT06223581
Evaluation of Cardiac Burden in Patients With Sever Bronchial Asthma
An observational study of Evaluation of Cardiac Burden in Patients With Sever Bronchial Asthma, run by Assiut University.
Trial summary
Evaluation of cardiac burden in patients with sever bronchial asthma Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Evaluation of Cardiac Burden in Patients With Sever Bronchial Asthma
- What is being tested?
- ECHO in sever asthma patient
- How many people
- 30 participants
- Where
- No sites listed yet
- Study dates
- 17 Jan 2024to 1 Apr 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Adult
Study population: Bronchial asthma is chronic bronchial inflammation of variable intensity accompanied by recurrent reversible airflow obstruction and symptoms such as coughing, wheezing, shortness of breath, and chest tightness ,with a worldwide increase over the last several decades . 1. Sever asthma :means that asthma is uncontrolled despite adherence with maximal optimized therapy and treatment contributory factors or that worsens when high dose treatment is reduced. 2. Globally. over 260 million people had poorly controlled asthma highest rate on Australia.3-3-Heart diseases are the most common cause of
Who may be able to join
- Patients accepted to be involved in the study.
- Patients >18 years old .
Who cannot join
- severe bronchial asthma patients who have other comorbidities as (chronic chest disease as COPD,ILD, bronchiectasis , , diabetic ,hypertensive ,mechanical ventilated patients, tracheostomized patients, ……)
- patients <18 years old . patients refuse to be involved in the study .
About this study
Evaluation of cardiac burden in patients with sever bronchial asthma
Read the detailed description
Bronchial asthma is chronic bronchial inflammation of variable intensity accompanied by recurrent reversible airflow obstruction and symptoms such as coughing, wheezing, shortness of breath, and chest tightness ,with a worldwide increase over the last several decades (1).
- Sever asthma :means that asthma is uncontrolled despite adherence with maximal optimized therapy and treatment contributory factors or that worsens when high dose treatment is reduced.
- Globally. over 260 million people had poorly controlled asthma highest rate on Australia.
- Being tested
- ECHO in sever asthma patient
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ECHO in sever asthma patientOther
Evaluation of cardiac burden in patients with sever bronchial asthma
What is being measured
The primary outcome is the main question the study is designed to answer.
To Evaluation of cardiac burden in patients with sever bronchial asthma
For Early detection and avoidance of cardiac effects in severe asthma patients
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2024
- Study start17 Jan 2024 (estimated)
- Primary completion1 Jan 2026 (estimated)
- Study completion1 Apr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Evaluation of Cardiac Burden in Patients With Sever Bronchial AsthmaStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmad Hany Anwer Ahmed, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06223581
- Sponsor's protocol ID
- Cardiac burden in sever asthma
- Status last verified
- Jan 2024
- First submitted
- 22 Nov 2023
- Last updated
- 25 Jan 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Cardiac Burden in Patients With Sever Bronchial Asthma
- ClinicalTrials.gov ID
- NCT06223581
- Acronym / sponsor ID
- Cardiac burden in sever asthma
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 17 Jan 2024 (estimated)
- Primary completion
- 1 Jan 2026 (estimated)
- Study completion
- 1 Apr 2026 (estimated)
- First posted
- 25 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluation of cardiac burden in patients with sever bronchial asthma
Detailed description
Bronchial asthma is chronic bronchial inflammation of variable intensity accompanied by recurrent reversible airflow obstruction and symptoms such as coughing, wheezing, shortness of breath, and chest tightness ,with a worldwide increase over the last several decades (1).
- Sever asthma :means that asthma is uncontrolled despite adherence with maximal optimized therapy and treatment contributory factors or that worsens when high dose treatment is reduced.
- Globally. over 260 million people had poorly controlled asthma highest rate on Australia.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Age groups
- Adult
- Study population
- Bronchial asthma is chronic bronchial inflammation of variable intensity accompanied by recurrent reversible airflow obstruction and symptoms such as coughing, wheezing, shortness of breath, and chest tightness ,with a worldwide increase over the last several decades . 1. Sever asthma :means that asthma is uncontrolled despite adherence with maximal optimized therapy and treatment contributory factors or that worsens when high dose treatment is reduced. 2. Globally. over 260 million people had poorly controlled asthma highest rate on Australia.3-3-Heart diseases are the most common cause of
Key inclusion criteria (2 listed)
- Patients accepted to be involved in the study.
- Patients >18 years old .
Key exclusion criteria (2 listed)
- severe bronchial asthma patients who have other comorbidities as (chronic chest disease as COPD,ILD, bronchiectasis , , diabetic ,hypertensive ,mechanical ventilated patients, tracheostomized patients, ……)
- patients <18 years old . patients refuse to be involved in the study .
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ECHO in sever asthma patientEvaluation of cardiac burden in patients with sever bronchial asthma | Other | – |
Primary outcome
To Evaluation of cardiac burden in patients with sever bronchial asthma
Time frame: Baseline
For Early detection and avoidance of cardiac effects in severe asthma patients
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2024.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Evaluation of Cardiac Burden in Patients With Sever Bronchial Asthma, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To Evaluation of cardiac burden in patients with sever bronchial asthma (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2024.